For millions of Americans, telehealth has turned a once-out-of-reach class of medicine into an affordable reality. Compounded GLP-1 medications for weight loss and diabetes now reach patients online for a median of about $175 a month. Compounded medication is a lifeline for patients, particularly those who cannot handle standard doses or who have allergies to specific ingredients. This improved access provides a savings of about $14,000 a year for individual patients, according to Forbes Health. That is free enterprise doing exactly what it should: widening access and driving down costs. So it is worth paying close attention when a federal agency quietly narrows how these companies are allowed to describe themselves.
In June, the FDA published new guidance reminding telehealth companies how they may and may not promote compounded drugs. Most of it is uncontroversial consumer protection. Barring companies from claiming their products are FDA-approved when they are not, or clinically proven when no trials exist, is exactly the kind of rule against falsehoods the First Amendment permits. But the very first item on the FDA’s list reaches past banning falsehoods into something murkier, and it carries a serious constitutional problem.
The Government Is Banning an Inference, Not a Falsehood
The core problem is simple: this rule bans an inference the FDA thinks customers might draw, without any evidence they draw it. The guidance’s first prohibition targets branding that “falsely or misleadingly implies” a telehealth company is its own compounder. That word, implies, is doing enormous legal work. Every other prohibition on the list addresses a verifiable false statement. This one targets an inference consumers are unlikely to draw – consumers think in terms of brands, not pharmaceutical supply chains – and one the FDA has offered no evidence that they do draw.
Modern telehealth companies frequently facilitate the fulfillment of their customers’ prescribed treatments through affiliated compounding entities, white-label pharmacy arrangements, or co-branded partnerships with licensed facilities. Marketing assets that feature the telehealth platform’s brand name are accurately describing a real business relationship. Under the FDA’s new language, the FDA is seemingly prohibiting companies from advertising with accurate branding. Companies are left guessing at what compliance actually requires.
The Constitution Protects Truthful Speech, Even When Some Might Misread It
The Supreme Court has drawn a firm line between commercial speech that is actually misleading, which the government may regulate, and speech that is only potentially misleading to some consumers, which it generally may not (In re R.M.J.). An implication-based standard erases that line. If the FDA can suppress branding because it thinks some subset of consumers might draw an incorrect inference, even when the branding accurately describes a real corporate structure, the agency has stopped policing deception and started policing communication it simply finds inconvenient. The Court has repeatedly rejected that kind of paternalism.
The problem deepens because the rule singles out one set of speakers. Since Sorrell v. IMS Health, courts apply heightened scrutiny to content-based commercial-speech restrictions, especially those that burden particular speakers. A rule dictating how telehealth companies may present their branding, while placing no equivalent constraint on brand-name manufacturers, puts a government thumb on the competitive scale. To survive, the government must show its restriction directly and materially advances a substantial interest, and speculative confusion, rooted in an inference rather than any false statement, does not come close.
Vague Speech Rules Chill Truthful Speech
There is a practical problem that doubles as a constitutional one. The guidance tells companies what they cannot imply, but says nothing about what compliant branding looks like. No examples. No safe harbors. No description of permissible structures.
When regulatory ambiguity attaches to expressive choices, the predictable result is overcorrection: companies strip away truthful branding rather than gamble on enforcement. That chilling effect is innovation-killing red tape, suppressing accurate speech the government never needed to reach. And the burden falls hardest on lower-cost challengers, at a time when legacy manufacturers have a long, well-documented history of urging regulators to raise barriers against cheaper competitors.
The Constitutional Fix Is Disclosure, Not Prohibition
A better tool is readily available. If the FDA is genuinely worried that consumers might misunderstand the relationship between a telehealth platform and its compounding partner, it can require clear disclosure of that relationship. A simple line such as “compounded by [pharmacy name]” or “fulfilled through our affiliated compounding facility” resolves any ambiguity without silencing a single truthful statement. Disclosure informs consumers where prohibition merely silences, and the First Amendment has always preferred the former.
The FDA’s underlying concerns are not imaginary. Manufacturing standards, quality control, and dose consistency deserve real regulatory attention. But the agency has reached for a blunt instrument when a precise one was in hand. The FDA should protect patients the constitutional way: with disclosure that informs consumers rather than vague prohibitions that punish the very companies making this medicine affordable. That is how we keep both free expression and free enterprise working for American patients.
Image from Unsplash